|
|
5-day change | 1st Jan Change | ||
|
2,508.00 JPY |
-10.11% |
|
-14.72% | -25.13% |
Published on 04/23/2026
at 09:59 pm EDT
MT Newswires
This article is reserved for members Unlock the article: REGISTER NOW!
© MT Newswires –
2026
| 09:59pm |
Daiichi Sankyo Raises Full-Year Forecasts on Forex Gains |
MT |
| 09:31pm |
Daiichi Sankyo Delays Earnings Release Amid Oncology Portfolio Review; Shares Fall 10% |
MT |
| 07:34pm |
Daiichi Sankyo Co Ltd – Daiichi Sankyo announces rescheduling of announcement of consolidated financial results for year ended March 31, 2026 |
RE |
Apr. 16 |
Aktis Oncology, Inc. Announces Board and Board Committee Changes |
CI |
Apr. 16 |
Interna Therapeutics and Daiichi Sankyo Enters Research Collaboration to Advance Mnm-Based Targeted Delivery Technologies |
CI |
Apr. 15 |
Global markets live: Amazon, BoA, Broadcom, Gitlab, Stellantis… |
 |
Apr. 15 |
Wayfinder Biosciences and Daiichi Sankyo Advance Research Collaboration on Key Neurodegeneration Target to Second Phase |
CI |
Apr. 15 |
Daiichi Sankyo to Sell Over-the-Counter Drug Business for $1.55 Billion |
DJ |
Apr. 15 |
Suntory Eyes Daiichi Sankyo Healthcare in 200 Billion Yen Deal |
MT |
Apr. 15 |
Suntory Holdings Ltd – By welcoming Daiichi Sankyo healthcare to Suntory group, expect to expand business across self-care and self-medication domains |
RE |
Apr. 15 |
Daiichi Sankyo Co Ltd – to transfer Daiichi Sankyo healthcare stock to Suntory Holdings |
RE |
Apr. 14 |
Suntory Holdings to buy Daiichi Sankyo Healthcare for about 200 billion yen, Nikkei says |
RE |
Apr. 14 |
Suntory Holdings Limited signed a letter of intent to acquire Daiichi Sankyo Healthcare Co., Ltd. from Daiichi Sankyo Company, Limited for approximately ¥250 billion. |
CI |
Apr. 14 |
4D Path and Daiichi Sankyo Announce Collaboration to Advance Ai-Driven Predictive Biomarkers for an Antibody Drug Conjugate Program |
CI |
Apr. 13 |
Daiichi Sankyo Co Ltd – Ifinatamab deruxtecan granted Priority Review in the United States for adult patients with previously treated extensive-stage small cell lung cancer who experienced disease progression on or after platinum-based chemotherapy |
RE |
Daiichi Sankyo Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical producing in Japan, the United States, Europe and other markets. The Company is also engaged in the research, development, manufacture and sale of over-the-counter drugs and vaccines, the provision of administrative services such as human resources and accounting services, real estate leasing and insurance agency business.
Trader
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Buy
Last Close Price
2,790.00JPY
Average target price
4,640.00JPY
Spread / Average Target
+66.31%
Quarterly revenue – Rate of surprise
Select your edition
All financial news and data tailored to specific country editions
www.marketscreener.com